Company* | Product | Description | Indication | Status (Date) |
| | ||||
CANCER | ||||
Oxxon Pharmaccines | Prime- | Vaccine involving | Melanoma | Phase I results showed it was well tolerated; company is moving it into Phase II trials in the UK (10/14) |
SuperGen Inc. | Paclitaxel | Chemotherapy compound | Cancer | EuroGen filed a mutual recognition application in the UK, seeking regulatory approval to market paclitaxel in the UK and certain other countries within the European Union (10/28) |
CENTRAL NERVOUS SYSTEM |
||||
ExonHit | EHT | Pentoxifylline; | Amyotrophic lateral | Company initiated its first clinical Phase II trial in Europe (10/22) |
Pozen Inc. | MT 100 | An oral migraine | Migraine | Company submitted to the UK regulatory authorities a marketing authorization application (10/8) |
DIABETES | ||||
Amylin Pharma- | Symlin | Pramlintide acetate; an | Diabetes | Company withdrew its marketing application in Europe after regulatory officials said additional information may be necessary for approval (10/24) |
INFECTION |
||||
AuRx Inc.* | - | Vaccine | Genital herpes | Phase I/II trial results in Mexico showed there were no treatment- related adverse events and the side effects were similar to that of a sugar pill (10/11) |
VaxGen Inc. | AIDSVAX | AIDS vaccine made | AIDS | Phase III data from a study in Thailand showed the vaccine appears safe (10/21) |
MISCELLANEOUS |
||||
Genaera | Lomucin | Oral mucoregulator | Cystic fibrosis | Company will begin a Phase II trial in Ireland (10/18) |
| | ||||
Notes: | ||||
* Privately held. |
||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. |
||||
TSE = Toronto Stock Exchange |
||||
